Search results
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
Zacks via Yahoo Finance· 4 days agoGSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling...
Zantac Heart Burn Continues For GSK As US Court Ruling Allows Thousands Of Zantac Lawsuits To Move...
Benzinga via Yahoo Finance· 4 days agoOn Monday, GSK Plc (NYSE:GSK) shares were down after the Delaware State Court ruled that more than...
Sarclisa Combination Improves Progression-Free Survival in Patients with Newly Diagnosed...
Pharmaceutical Executive Magazine· 3 days agoResults from the IMROZ Phase III trial show that Sanofi’s Sarclisa (isatuximab-irfc) in combination...
Novavax says it will have an updated Covid vaccine - Washington Business Journal
The Business Journals· 19 hours agoGaithersburg’s Novavax Inc. (NASDAQ: NVAX) says it will have an updated Covid-19 vaccine ready in...
GSK Plunges as Drugmaker Must Face Zantac Cases in Delaware
Bloomberg· 4 days agoGSK Plc shares plunged in the wake of a court ruling that the UK drugmaker, alongside others...
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
Zacks· 3 days agoFree Report) announced that the FDA has selected experimental candidate DNL126 in support of clinical trials advancing the rare disease therapeutics (START) Pilot Program. The candidate is an ...
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
Zacks· 3 days agoTeva Pharmaceutical Industries Limited’s (TEVA Quick QuoteTEVA - Free Report) revenues have suffered...
Health Care Roundup: Market Talk
The Wall Street Journal· 4 days ago(andrea.figueras@wsj.com) 0331 ET – Global Health looks strategically positioned for substantial growth, Axis Securities analyst Ankush Mahajan says in a...
Health Care Roundup: Market Talk
The Wall Street Journal· 3 days agoThe Indonesia-based hospital operator expects to add 250-300 beds by ramping up operations of its existing hospitals, boosting overall bed capacity and...
Leonard Schleifer
Fortune· 3 days agoThe company may have just the prescription to keep profits flush: The FDA recently approved its first-in-class anti-cholesterol drug—developed with Sanofi and priced, at $14,600 ...
